MaxCyte Expects Q1 Sales To Beat Expectations, CFO Resigns

Comments
Loading...
  • MaxCyte Inc MXCT appointed Ron Holtz, current Senior Vice President, and Chief Accounting Officer, as the Interim Chief Financial Officer.
  • The change comes as Amanda Murphy has resigned from her position as Chief Financial Officer, effective as of April 15, 2022, to pursue other interests. 
  • MaxCyte also expects Q1 FY22 sales of at least $11.0 million, versus the consensus of $8.46 million and $6.5 million in Q1 FY21.
  • Core business revenue is expected to be at least $9.0 million, and SPL Program-related revenue is expected to be $2.0 million. 
  • The Company has engaged executive search firm Korn Ferry to lead a search for a new Chief Financial Officer.
  • Price Action: MXCT shares closed 1.92% higher at $5.85 during after-hours trading on Tuesday.
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!